Capmatinib improves insulin sensitivity and inflammation in palmitate-treated C2C12 myocytes through the PPARĪ“/p38-dependent pathway
Sign Up to like & getrecommendations! Published in 2021 at "Molecular and Cellular Endocrinology"
DOI: 10.1016/j.mce.2021.111364
Abstract: Capmatinib (CAP) has been used to treat metastatic non-small lung cancer (NSCL) and suppress inflammation. It causes hypoglycemia in NSCL patients. Therefore, it is expected that CAP improves inflammation-mediated insulin resistance due to its anti-inflammatory… read more here.
Keywords: palmitate treated; palmitate; treated c2c12; inflammation ... See more keywords